China Pharma Holdings (CPHI) Common Equity (2010 - 2026)

China Pharma Holdings (CPHI) has reported Common Equity for 17 consecutive years, with $36.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 459.93% year-over-year to $36.2 million; the trailing twelve-month figure through Jun 2026 stood at $36.2 million (up 459.93% YoY), and the FY2025 full-year result was $22.7 million, up 193.5% from the prior year.
• Common Equity slipped to $36.2 million in Q2 2026 per CPHI's latest filing, from $37.0 million in the prior quarter.
• Across five years, Common Equity topped out at $37.0 million in Q1 2026 and bottomed at $2.8 million in Q3 2022.
• Historically, Common Equity has averaged $10.4 million across 5 years, with a median of $6.7 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Common Equity sank 58.64% in 2022, then jumped 459.93% in 2026.
• Over 5 years, Common Equity stood at $4.3 million in 2022, then surged by 73.77% to $7.5 million in 2023, then gained by 3.93% to $7.7 million in 2024, then surged by 193.5% to $22.7 million in 2025, then surged by 59.11% to $36.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $36.2 million, $37.0 million, and $22.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.